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Abstract
Pyrazinamide resistance is largely unknown in the spectrum of drug resistant phenotypes. We 
summarize data on PZA resistance in clinical isolates from South Africa. PZA DST should be 
performed when considering its inclusion in treatment of patients with rifampicin-resistant TB or 
MDR-TB.
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Pyrazinamide (PZA) is a critical component of the first-line tuberculosis (TB) treatment 
regimen [1]. The unique ability of PZA to target subpopulations of persister bacteria has 
significantly reduced the treatment duration from 9–12 to 6 months [2]. The importance of 
PZA is further highlighted by its inclusion in the latest WHO recommended multi-drug 
resistant (MDR)-TB treatment regimen [3] as well as most novel MDR-TB regimens 
presently under investigation [4].
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Little is known regarding the prevalence of PZA drug resistance, largely because drug 
susceptibility testing (DST) of PZA is not yet standardized and thus not routinely 
implemented in high burden countries. The BACTEC Mycobacteria Growth Indicator Tube 
(MGIT) 960 system PZA (BD Diagnostic Systems, NJ, USA) recently became the reference 
technique, but concerns remain since false resistance may occur with this system [5]. False 
resistance may occur due to inoculum size or the presence of bovine serum albumin in the 
media of the MGIT 960 DST.[6]
Mutations in pncA are the primary mechanism of resistance to PZA [7]. It is hypothesized 
that these mutations decrease pyrazinamidase (PZase) activity, thereby limiting the 
conversion of PZA to the active form of pyrazinoic acid (POA) [7]. A high sensitivity (92%) 
and specificity (93%) for PCR-DNA sequencing when compared to the phenotypic DST 
supports the use of genotypic DST for the identification of PZA resistance [8]. Extensive 
DNA sequencing studies of pncA have revealed that mutations occur across the entire length 
of the gene, making it a complex target for a molecular diagnostic to identify all causal 
mutations [9, 10]. Furthermore, not all non-synonymous mutations cause phenotypic 
resistance [6], and mutations in the pncA gene are absent in a small percentage of 
phenotypically PZA resistant isolates [11] suggesting that resistance could be conferred via 
an alternative mechanism(s), such as the gene rpsA or panD [12, 13].
Several studies have investigated the prevalence of PZA resistance in drug susceptible as 
well as MDR-TB isolates. In a recent meta-analysis, the prevalence of PZA resistance was 0 
– 9% among drug susceptible and 31 – 89% among MDR-TB isolates [8]. Data is scarce on 
the prevalence of PZA resistance in RIF mono-resistant, INH mono-resistant, extensively 
drug resistant (XDR) and pre-XDR TB isolates.
This study aimed to determine the association between mutations in the pncA gene and 
phenotypic resistance to PZA and to investigate the prevalence of PZA resistance across the 
spectrum of drug resistant isolates, from pan-susceptible TB to XDR-TB.
 Materials and Methods
 Study samples
A convenience sample of 775 drug resistant clinical isolates classified as INH mono-
resistant, RIF mono-resistant or MDR-TB by the National Health Laboratory Services 
(NHLS) was selected. Routine DST for INH and RIF at the NHLS was done using either 
MGIT culture or the GenoType MTBRplus (Hain LifeScience) line probe assay (LPA).
 Phenotypic DST of INH, RIF and PZA
At the MRC Centre for Tuberculosis Research laboratory, all selected isolates were 
subjected to phenotypic INH, RIF and PZA susceptibility testing using the BACTEC MGIT 
960 method (BD Diagnostic Systems, NJ, USA). Growth at a critical concentration of 
0.1µg/ml INH, 1.0µg/ml RIF, and 100µg/ml PZA was used to define resistance [14].
Whitfield et al. Page 2





















 Genotypic classification of isolates
DNA sequencing of the gyrA and rrs gene was done to identify pre-XDR-TB and XDR-TB, 
as previously described [15]. DNA sequencing of the pncA, panD and rpsA genes were done 
to identify PZA resistance, as previously described [12, 13, 16]. No restriction fragment 
length polymorphism (RFLP) genotyping was performed.
 Statistics
We used the Cochran-Armitage test in R to assess the presence of a trend in prevalence of 
PZA resistance by levels of resistance to other drugs.
 Results
 Phenotypic and genotypic characterisation of isolates
Based on phenotypic and genotypic DST performed at the research laboratory, 80 (10.3%) 
isolates were classified as pan-susceptible, 98 (12.7%) as INH mono-resistant; 279 (36.0%) 
as RIF mono-resistant, 224 (28.9%) as MDR-TB and 94 (12.1%) as pre-XDR and XDR-TB. 
Of the 80 pan-susceptible and 98 INH mono-resistant samples, 96 were confirmed 
rifampicin susceptible by molecular methods (MTBDRplus, Xpert MTB/RIF, rpoB 
sequencing). Low level rifampicin resistance may have been missed among the 82 samples 
evaluated only by MGIT960 DST, possibly resulting in some misclassification of samples as 
rifampicin susceptible.
 Correlation of genotypic and phenotypic PZA resistance by level of resistance to other 
TB drugs
Overall, 246 (31.7%) isolates had a polymorphism in the pncA gene: 29 (11.8%) 
synonymous single nucleotide polymorphisms (SNP), 126 (51.2%) non-synonymous SNPs, 
80 (32.5%) insertions and 11 (4.5%) deletions. Among all 775 isolates, 15 had discordant 
results between genotypic and phenotypic DST after considering SNPs known to not confer 
resistance to PZA at 100µg/ml [6]. Most discrepancies (10/15) were phenotypically resistant 
despite the presence of wild type pncA gene. The remaining 5 discrepancies were 
phenotypically susceptible with a non-synonymous change in the pncA gene (TTC13TGC, 
TGC72GGC, GCG102GTG, GTG139GGG). Using the phenotypic DST results as the 
reference standard, genotypic DST had an overall sensitivity of 95.0 (95% CI 92.1 – 98.0) 
and specificity of 99.1 (95% CI 98.4 – 99.9). The strong correlation between phenotypic 
PZA-resistance and changes in the pncA gene was observed independent of the resistance 
profile to other TB drugs. DNA sequencing of the panD gene failed to identify any 
mutations, sequencing of the rpsA gene identified one synonymous mutation 
(CGA212CGC) not associated with resistance [12].
 Phenotypic PZA resistance by level of resistance to other TB drugs
Using the BACTEC MGIT 960 system, the number of isolates resistant to PZA at critical 
concentration of 100µg/ml was: 0 of 80 (0.0%) pan-susceptible isolates, 2 of 98 (2.0%; 95% 
CI 0, 4.8) INH mono-resistant isolates, 21 of 279 (7.5%; 95% CI 4.4, 10.6) RIF mono-
resistant isolates, 88 of 224 (39.3%; 95% CI 32.9, 45.7) MDR isolates, and 91 of 94 (96.8%; 
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95% CI 93.2, 100) pre-XDR-TB and XDR-TB isolates (Figure 1). The proportion of isolates 
with PZA resistance increased significantly with increasing resistance to other drugs 
(Cochran-Armitage test, p =< 0.0005).
 Discussion
We found a significant increase in the prevalence of PZA resistance with increasing level of 
resistance (pan-susceptible (0%) to pre-XDR and XDR-TB (96.8%)). These findings extend 
prior observations of low prevalence of PZA resistance in pan-susceptible but high 
prevalence of PZA resistance in MDR-TB isolates [8, 10]. Our findings strongly suggest that 
patients with pan-susceptible and INH mono-resistance benefit from inclusion of PZA in 
their treatment regimen and that PZA DST should be routinely performed in patients with 
RIF mono-resistance and MDR-TB. Lastly that the inclusion of PZA in treatment regimens 
for pre-XDR and XDR regimen is likely to cause more harm due to side effects than benefit 
since 97% (95% CI 93, 100) of all pre-XDR and XDR-TB isolates were resistant to PZA.
Similar to other studies, we found an excellent correlation between phenotypic and 
genotypic DST with an overall sensitivity of 95.0% (95% CI 92.1 – 98.0) and a specificity of 
99.1% (95% CI 98.4 – 99.9). We further observed that this strong correlation was 
independent of the resistance profile to other TB drugs. Taken together, these observations 
provide mounting evidence supporting the use of genotypic instead of the slow and 
cumbersome phenotypic DST for PZA [10]. Use of genotypic DST could however result in 
some misclassification due to the existence of silent mutations and resistance not conferred 
by mutations in the pncA gene [6]. In our study, the occurrence of discordances was rare, 
similar to other studies findings [11]. Finally, the role of some pncA mutations is unclear as 
two mutations (GCG102GTG, GTG139GGG) were found to be susceptible in our study but 
resistant in another study [10].
 Conclusion
The prevalence of PZA resistance is strongly correlated with resistance to rifampicin and 
increases with additional resistance in MDR and XDR-TB strains. The presence of 
rifampicin-resistance could then be considered as an indicator to perform DST to PZA‥ 
Consideration should also be given when defining the role of PZA in future TB treatment 
regimens.
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